Central European Journal of Medicine

, Volume 4, Issue 1, pp 119–124 | Cite as

High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis

  • Martin A. Malý
  • Ivana Hadačová
  • Petr Hájek
  • David Zemánek
  • Josef Veselka
Case Report


High-residual platelet activity despite the dual antiplatelet treatment with aspirin and clopidogrel is associated with major adverse cardiac events, including stent thrombosis. Acute and subacute stent thrombosis is rare, but presents itself with serious complications including high mortality and morbidity rates. Light transmittance aggregometry with specific agonists — arachidonic acid and 5-adenosin diphosphate — is still considered a standard for the assessment of platelet reactivity, besides novel methods like vasodilator-stimulated phosphoprotein phosphorylation. In our case study, we report the coincidence of high-residual platelet activity with subacute stent thrombosis despite the recommended doses of antiplatelet agents — aspirin and clopidogrel. Stent thrombosis was treated by aspiration thrombectomy, and antiplatelet treatment was modified by increasing the dose of aspirin and substituting clopidogrel with a firstgeneration thienopyridin — ticlopidin. The effect of the treatment was documented by reaching the optimal inhibition of platelet reactivity. In the 6- and 12-month follow-up, the patient presented no ischemic events.


Resistance Dual antiplatelet therapy Stent thrombosis Light transmittance aggregometry Clopidogrel 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Park S.J., Lee S.W., Optimal management of platelet function after coronary stenting., Curr. Treat. Options. Cardiovasc. Med., 2007, 9, 37–45PubMedCrossRefGoogle Scholar
  2. [2]
    Bonello L., Camoin-Jau L., Arques S., Boyer C.H., Panagides D., Wittenberg O., et al., Adjusted clopidogrel loading doses according to Vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major averse cardiovascular events in patiens with clopidogrel resistence., J. Am. Coll. Cardiol., 2008, 14, 1404–11CrossRefGoogle Scholar
  3. [3]
    Gum P.A., Mottle-Marchant K., Welsh P.A., White J., Topol E.J., A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease., J. Am. Coll. Cardiol., 2003, 41, 961–5PubMedCrossRefGoogle Scholar
  4. [4]
    Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al., Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study., J. Am. Coll. Cardiol., 2005, 46, 1820–1826PubMedCrossRefGoogle Scholar
  5. [5]
    Regar E., Lemos P.A., Saia F., Degertekin M., Tanabe K., Lee C.H., et al., Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients., Am. J. Cardiol., 2004, 93, 1271–75PubMedCrossRefGoogle Scholar
  6. [6]
    Cutlip D.E., Baim D.S., Ho K.K., Popma J.J., Lansky A.J., Cohen D.J., et al., Stent thrombosis in the modern area: pooled analysis of multicenter coronary stent clinical trials., Circulation., 2001, 103, 1967–71PubMedGoogle Scholar
  7. [7]
    Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al., Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study., J. Am. Coll. Cardiol., 2005, 46, 1827–32PubMedCrossRefGoogle Scholar
  8. [8]
    Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A., Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention., J. Am. Coll. Cardiol., 2007, 49, 657–66PubMedCrossRefGoogle Scholar
  9. [9]
    Watala C., Chudzik A., Tchorzewski H., Gwozdzinski K., Impaired action of nitric oxide on blood platelets in premature newborns., Arch. Med. Sci., 2008, 4, 315–323Google Scholar
  10. [10]
    Boncler M., Gresner P., Nocun M., Rywaniak J., Dolnik M., Rysz J., Wilk R., Czyz M., Markuszewski L., Banach M., Watala C., Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation., Biochim. Biophys. Acta., 2007, 1770, 1651–9PubMedGoogle Scholar
  11. [11]
    Veselka J., Zemánek D., Duchoňová R., Blaško P., Adla T., Tesař D., Neuwirth J., Coronary angiography and dual-source computed tomography are complementary methods in diagnosis of significant stenosis of the right coronary artery originating from the left aortic sinus., Cent. Eur. J. Med., 2008, 3,111–114CrossRefGoogle Scholar
  12. [12]
    Colombo A., Hall P., Nakamura S., Almagor Y., Maiello L., Martini G., et al., Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance., Circulation., 1995, 91, 1676–88PubMedGoogle Scholar
  13. [13]
    Hall P., Nakamura S., Maiello L., Itoh A., Blengino S., Martini G., et al., A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation., Circulation., 1996, 93, 215–22PubMedGoogle Scholar
  14. [14]
    Moussa I., Di Mario C., Reimers B., Akiyama T., Tobis J., Colombo A., Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome., J. Am. Coll. Cardiol., 1997, 29, 6–12PubMedCrossRefGoogle Scholar
  15. [15]
    Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction., Circulation., 2004, 109, 3171–75PubMedCrossRefGoogle Scholar
  16. [16]
    Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al., Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation., Catheter. Cardiovasc. Interv., 2003, 59, 295–302PubMedCrossRefGoogle Scholar
  17. [17]
    Gurbel P.A., Bliden K.P., Hiatt B.L., O’Connor C.M., Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity., Circulation., 2003, 107, 2908–13PubMedCrossRefGoogle Scholar
  18. [18]
    Geisler T., Langer H., Wydymus M., Gohring K., Zurn C.H., Bigalke B., et al., Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation., Eur. Heart. J., 2006, 27, 2420–25PubMedCrossRefGoogle Scholar
  19. [19]
    Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al., High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome., J. Thromb. Haemost., 2006, 4, 542–49PubMedCrossRefGoogle Scholar
  20. [20]
    Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D., Platelet function monitoring in patients with coronary artery disease., J. Am. Coll. Cardiol., 2007, 19, 1822–34CrossRefGoogle Scholar
  21. [21]
    Michelson A.D., Platelet function testing in cardiovascular diseases., Circulation., 2004, 110, 489–93CrossRefGoogle Scholar
  22. [22]
    Ingerman C., Smith J.B., Silver M.J., Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP and an accumulation of radiolabeled platelets., J. Lab. Clin. Med., 1983, 101, 44–52Google Scholar
  23. [23]
    Geiger J., Brich J., Hönig-Liedl P., Eigenthaler M., Schanzenbächer P., Herbert J.M., et al., Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel., Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2007–11PubMedGoogle Scholar
  24. [24]
    Gori A.M., Marcucci R., Migliorini A., Valenti R., Moschi G., Paniccia R., et al., Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents., J. Am. Coll. Cardiol., 2008, 52, 734–39PubMedCrossRefGoogle Scholar
  25. [25]
    Campo G., Valgimigli M., Gemmati D., Percoco G., Catozzi L., Frangione A., et al., Poor responsiveness to clopidogrel: drug-specific or class effect mechanism?, J. Am. Coll. Cardiol., 2007, 12, 1132–37CrossRefGoogle Scholar
  26. [26]
    Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al., TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes., N. Engl. J. Med., 2007, 357, 2001–15PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Martin A. Malý
    • 1
  • Ivana Hadačová
    • 2
  • Petr Hájek
    • 1
  • David Zemánek
    • 1
  • Josef Veselka
    • 1
  1. 1.CardioVascular Center, Department of CardiologyUniversity Hospital Motol, 1st Medical FacultyPragueCzech Republic
  2. 2.Department of HematologyUniversity Hospital MotolPragueCzech Republic

Personalised recommendations